Add to ORKGAn economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain
Varenicline tartrate, a selective partial agonist of the alpha alpha 4 beta beta 2 nicotinic recepto...
To evaluate the cost-effectiveness of an additional 12-week treatment with varenicline for abstainer...
STUDY OBJECTIVES: To calculate incremental cost-utility ratios (cost per QALY gained) for vareniclin...
Background: An estimated 17.2% of patients continue to smoke following diagnosis of cardiovascular d...
Background: An estimated 17.2% of patients continue to smoke following diagnosis of cardiovascular d...
The EUROACTION PLUS trial measured the effectiveness of a nurse-led preventive cardiology programme ...
Michele A FaulknerCreighton University School of Pharmacy and Health Professions, Omaha, NE, USAAbst...
Smoking cessation lowers the risk of death substantially in patients with cardiovascular disease. Al...
The impact of the Danish smoking ban on hospital admissions for acute myocardial infarctio
Rasch A, Lenz C, Greiner W. Health economic model of smoking cessation treatment with varenicline in...
<p>Smoking is a major risk factor in patients with angina pectoris. Interventions that facilitate th...
Background and Objective: Varenicline is a nicotinic acetylcholine receptor partial agonist that is ...
The morbidity and mortality rates attributed to smoking are substantial and cigarette smoke remains ...
Background—Smoking cessation is a key component of secondary cardiovascular disease prevention. Vare...
Background: Chronic Stable Angina (CSA) does not respond to clinical interventions always. Therefore...
Varenicline tartrate, a selective partial agonist of the alpha alpha 4 beta beta 2 nicotinic recepto...
To evaluate the cost-effectiveness of an additional 12-week treatment with varenicline for abstainer...
STUDY OBJECTIVES: To calculate incremental cost-utility ratios (cost per QALY gained) for vareniclin...
Background: An estimated 17.2% of patients continue to smoke following diagnosis of cardiovascular d...
Background: An estimated 17.2% of patients continue to smoke following diagnosis of cardiovascular d...
The EUROACTION PLUS trial measured the effectiveness of a nurse-led preventive cardiology programme ...
Michele A FaulknerCreighton University School of Pharmacy and Health Professions, Omaha, NE, USAAbst...
Smoking cessation lowers the risk of death substantially in patients with cardiovascular disease. Al...
The impact of the Danish smoking ban on hospital admissions for acute myocardial infarctio
Rasch A, Lenz C, Greiner W. Health economic model of smoking cessation treatment with varenicline in...
<p>Smoking is a major risk factor in patients with angina pectoris. Interventions that facilitate th...
Background and Objective: Varenicline is a nicotinic acetylcholine receptor partial agonist that is ...
The morbidity and mortality rates attributed to smoking are substantial and cigarette smoke remains ...
Background—Smoking cessation is a key component of secondary cardiovascular disease prevention. Vare...
Background: Chronic Stable Angina (CSA) does not respond to clinical interventions always. Therefore...
Varenicline tartrate, a selective partial agonist of the alpha alpha 4 beta beta 2 nicotinic recepto...
To evaluate the cost-effectiveness of an additional 12-week treatment with varenicline for abstainer...
STUDY OBJECTIVES: To calculate incremental cost-utility ratios (cost per QALY gained) for vareniclin...